Leukocyte News and Research

RSS

MedImmune starts phase 2 trial of antibody targeting IL-5 receptor

MedImmune has announced that it has initiated a Phase 2 clinical trial in patients with chronic asthma to determine the safety of subcutaneous dosing of a humanized monoclonal antibody (MAb) that targets the interleukin-5 receptor (IL-5R).

8 Dec 2008

Scientists pinpoint immune-system targets in complex pathogens

Our immune cells have an amazingly intricate recognition system to detect invading pathogens. Often, the intricacies have overwhelmed scientists who want to know exactly what gives an alarm signal to T cells, a class of white blood cells that recognizes invaders.

7 Dec 2008

Two simple blood tests detect flesh-eating bacteria

With less than half of patients with necrotizing soft tissue infections displaying the physical signs of these very serious infections, researchers have found two simple blood tests can help physicians diagnose what is commonly known as "flesh-eating bacteria," according to a study in the December issue of The American Journal of Surgery.

5 Dec 2008

Scientists show that endothelial cells give rise to blood stem cells

Stem cell researchers at UCLA have proven definitively that blood stem cells are made during mid-gestational embryonic development by endothelial cells, the cells that line the inside of blood vessels.

3 Dec 2008

Natural killer T cells play important role in Lyme disease

A research team led by the La Jolla Institute for Allergy & Immunology and Albany Medical College has illuminated the important role of natural killer (NK) T cells in Lyme disease, demonstrating that the once little understood white blood cells are central to clearing the bacterial infection and reducing the intensity and duration of arthritis associated with Lyme disease.

3 Dec 2008

Scientists discover how ovarian tumors evade immune system

Scientists at Johns Hopkins have determined how the characteristic shedding of fatty substances, or lipids, by ovarian tumors allows the cancer to evade the body's immune system, leaving the disease to spread unchecked.

1 Dec 2008

FDA accepts Zevalin supplemental biologics license application

Cell Therapeutics, Inc. (CTI) has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application (sBLA) for use of Zevalin ([90Y]-ibritumomab tiuxetan) as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy. Priority review is granted by the FDA for a treatment that addresses a significant unmet medical need.

1 Dec 2008

Researchers discover genomic causes of acute lymphoblastic leukemia relapse

Scientists at St. Jude Children's Research Hospital have identified distinctive genetic changes in the cancer cells of children with acute lymphoblastic leukemia (ALL) that cause relapse.

28 Nov 2008

MorphoSys granted U.S. patent on antibodies against GM-CSF to treat inflammatory disorders

MorphoSys AG and the University of Melbourne announced today that the U.S. Patent & Trademark Office (USPTO) has confirmed that it will issue U.S. Patent No. 7,455,836, covering key uses of antibodies against GM-CSF.

25 Nov 2008

Researchers develop new strategy for broad spectrum anti-viral drugs

Bavituximab, an anti-viral drug developed by UT Southwestern Medical Center researchers, shows promise as a new strategy to fight viral diseases, including potential bioterrorism agents.

24 Nov 2008

Discovery of novel drug target for chronic lymphocytic leukemia

Researchers at the University of California, San Diego (UCSD) and the Moores UCSD Cancer Center have discovered what could be a novel drug target for an often difficult-to-treat form of leukemia.

24 Nov 2008

Nplate receives positive opinion for marketing authorisation in Europe

Amgen has announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for Nplate (romiplostim) in the European Union (EU).

21 Nov 2008

Scientists trick immune system of mice into believing transplanted islets are its own cells

The body's immune system hates strangers. When its security patrol spots a foreign cell, it annihilates it.

20 Nov 2008

FDA approves GSK's Promacta (Eltrombopag)

GlaxoSmithKline has announced that the United States Food and Drug Administration (FDA) granted accelerated approval for PROMACTA (eltrombopag) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

20 Nov 2008

Celator Pharmaceuticals enrols first patient in phase 2 study of CPX-351 in acute myeloid leukemia

Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).

19 Nov 2008

Common ADHD drugs do not cause genetic damage in children

In contrast to recent findings, two of the most common medications used to treat attention deficit hyperactivity disorder (ADHD) do not appear to cause genetic damage in children who take them as prescribed, according to a new study by researchers at the National Institutes of Health (NIH) and Duke University Medical Center.

19 Nov 2008

New research reveals key steps in HIV's assault on the brain

Scientists have unraveled in unprecedented detail the cascade of events that go wrong in brain cells affected by HIV, a virus whose assault on the nervous system continues unabated despite antiviral medications that can keep the virus at bay for years in the rest of the body.

16 Nov 2008

Gene chip technology used to rapidly and accurately detect pneumonia in ICU Patients on ventilators

Even seasoned doctors have a difficult time diagnosing pneumonia in hospitalized patients breathing with the assistance of a ventilator.

16 Nov 2008

All stem cells are not created equal, explains expert

During the course of the Presidential campaign, Obama signaled his intention to reverse Bush's controversial limit on federal funding of embryonic stem cell research.

11 Nov 2008

Medicine, math and engineering combine to reveal how sepsis and less severe infections occur

It's a leading cause of death, but no one knows for sure how and why it happens. It's a major source of health care costs, adding days or weeks to the hospital stays and lost work time of millions of people. But no one fully understands how best to fight it.

11 Nov 2008